Table of Contents

2018| October-December  | Volume 9 | Issue 4  

EDITORIAL
	Drug-resistant tuberculosis – A ticking time bomb!	p. 153
	Srikanth Krishnamurthy
	[ABSTRACT]  [HTML Full text]  [PDF]
ORIGINAL ARTICLES
	Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications	p. 155
	Pradeep Gadge, Roshani Gadge, Nikita Paralkar, Preeti Jain, Vrunda Tanna
	[ABSTRACT]  [HTML Full text]  [PDF]
	Comparison of efficacy and safety of topical 1% nadifloxacin and tretinoin 0.025% combination therapy with 1% clindamycin and tretinoin 0.025% combination therapy in patients of mild-to-moderate acne	p. 161
	Swapnil Narayan Deshmukh, Vandana Avinash Badar, Manali Mangesh Mahajan, D Sujata Dudhgaonkar, Dharmendra Mishra
	[ABSTRACT]  [HTML Full text]  [PDF]
	Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot	p. 165
	Kiran Gordhanbhai Piparva, Gaurav Jansari, Anil P Singh
	[ABSTRACT]  [HTML Full text]  [PDF]
REVIEW ARTICLES
	Comparative evaluation of pharmacovigilance regulation of the United States, United Kingdom, Canada, India and the need for global harmonized practices	p. 170
	Mohit Hans, Suresh Kumar Gupta
	[ABSTRACT]  [HTML Full text]  [PDF]
	Materiovigilance: An Indian perspective	p. 175
	Bikash Ranjan Meher
	[ABSTRACT]  [HTML Full text]  [PDF]
INVESTIGATOR INSIGHTS
	Investigator-initiated studies: Challenges and solutions	p. 179
	Mahanjit Konwar, Debdipta Bose, Nithya J Gogtay, Urmila M Thatte
	[ABSTRACT]  [HTML Full text]  [PDF]
STATISTICS
	Study designs: Part 1 – An overview and classification	p. 184
	Priya Ranganathan, Rakesh Aggarwal
	[ABSTRACT]  [HTML Full text]  [PDF]
LETTER TO EDITOR
	From “Glivec®” to “Prevnar 13®”: How strong is the Indian drug patenting system?	p. 187
	Gerard Marshall Raj
	[ABSTRACT]  [HTML Full text]  [PDF]